Copyright © 2012 Lie-Hang Shen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. D. F. Wong, G. Gründer, and J. R. Brasic, “Brain imaging research: does the science serve clinical practice?” International Review of Psychiatry, vol. 19, no. 5, pp. 541–558, 2007. View at Publisher · View at Google Scholar · View at Scopus
2. F. A. Metter and M. J. Guiberteau, “Radioactivity, radionuclides, and radiopharmaceuticals,” in Essentials of Nuclear Medicine Imaging, chapter 1, pp. 1–13, Saunders, Elsevier, 5th edition, 2006.
3. F. A. Metter and M. J. Guiberteau, “Positron emission tomography (PET) imaging,” in Essentials of Nuclear Medicine Imaging, chapter 13, pp. 359–423, Saunders, Elsevier, 5th edition, 2006.
4. R. Weissleder and U. Mahmood, “Molecular imaging,” Radiology, vol. 219, no. 2, pp. 316–333, 2001.
5. M. Fumita and R. B. Innis, Neuropsychopharmacology: The Fifth Generation of Progress, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 1st edition, 2002.
6. W. D. Heiss and K. Herholz, “Brain receptor imaging,” Journal of Nuclear Medicine, vol. 47, no. 2, pp. 302–312, 2006.
7. C. Sioka, A. Fotopoulos, and A. P. Kyritsis, “Recent advances in PET imaging for evaluation of Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 8, pp. 1594–1603, 2010. View at Publisher · View at Google Scholar
8. N. Pavese and D. J. Brooks, “Imaging neurodegeneration in Parkinson's disease,” Biochimica et Biophysica Acta, vol. 1792, no. 7, pp. 722–729, 2009. View at Publisher · View at Google Scholar · View at Scopus
9. N. Pavese, L. Kiferle, and P. Piccini, “Neuroprotection and imaging studies in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, supplement 4, pp. S33–S37, 2010. View at Publisher · View at Google Scholar · View at Scopus
10. J. P. Seibyl, “Imaging studies in movement disorders,” Seminars in Nuclear Medicine, vol. 33, no. 2, pp. 105–113, 2003. View at Publisher · View at Google Scholar · View at Scopus
11. D. J. Brooks, K. A. Frey, K. L. Marek et al., “Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease,” Experimental Neurology, vol. 184, supplement 1, pp. S68–S79, 2003. View at Publisher · View at Google Scholar · View at Scopus
12. J. O. Rinne, A. Laihinen, K. Någren, H. Ruottinen, U. Ruotsalainen, and U. K. Rinne, “PET examination of the monoamine transporter with [¹¹C]β-CIT and [¹¹C]β-CFT in early Parkinson's disease,” Synapse, vol. 21, no. 2, pp. 97–103, 1995. View at Publisher · View at Google Scholar · View at Scopus
13. J. O. Rinne, H. Ruottinen, J. Bergman, M. Haaparanta, P. Sonninen, and O. Solin, “Usefulness of a dopamine transporter PET ligand [¹⁸F]β-CFT in assessing disability in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 67, no. 6, pp. 737–741, 1999. View at Scopus
14. J. O. Rinne, E. Nurmi, H. M. Ruottinen, J. Bergman, O. Eskola, and O. Solin, “[¹⁸F]FDOPA and [¹⁸F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease,” Synapse, vol. 40, no. 3, pp. 193–200, 2001. View at Publisher · View at Google Scholar · View at Scopus
15. S. K. Meegalla, K. Plössl, M. P. Kung et al., “Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents,” Journal of Medicinal Chemistry, vol. 40, no. 1, pp. 9–17, 1997. View at Publisher · View at Google Scholar · View at Scopus
16. M. P. Kung, D. A. Stevenson, K. Plössl et al., “[${}^{99m}\text{Tc}$]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent,” European Journal of Nuclear Medicine, vol. 24, no. 4, pp. 372–380, 1997. View at Publisher · View at Google Scholar · View at Scopus
17. M. J. Ribeiro, M. Vidailhet, C. Loc'h et al., “Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease,” Archives of Neurology, vol. 59, no. 4, pp. 580–586, 2002. View at Scopus
18. J. Booij, G. Tissingh, A. Winogrodzka et al., “Practical benefit of [¹²³I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease,” European Journal of Nuclear Medicine, vol. 24, no. 1, pp. 68–71, 1997. View at Publisher · View at Google Scholar · View at Scopus
19. J. L. Cummings, C. Henchcliffe, S. Schaier, T. Simuni, A. Waxman, and P. Kemp, “The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration,” Brain, vol. 134, no. 11, pp. 3146–3166, 2011. View at Publisher · View at Google Scholar
20. B. Ravina, D. Eidelberg, J. E. Ahlskog et al., “The role of radiotracer imaging in Parkinson disease,” Neurology, vol. 64, no. 2, pp. 208–215, 2005. View at Scopus
21. H. H. Fernandez, J. H. Friedman, A. J. Fischman, R. B. Noto, and M. C. Lannon, “Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?” Medical Science Monitor, vol. 7, no. 6, pp. 1339–1343, 2001. View at Scopus
22. E. Nurmi, H. M. Ruottinen, J. Bergman et al., “Rate of progression in Parkinson's disease: a 6-[¹⁸F]fluoro-L-dopa PET study,” Movement Disorders, vol. 16, no. 4, pp. 608–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
23. W. S. Huang, Y. H. Chiang, J. C. Lin, Y. H. Chou, C. Y. Cheng, and R. S. Liu, “Crossover study of ${}^{99m}\text{Tc}$-TRODAT-1 SPECT and ¹⁸F-FDOPA PET in Parkinson's disease patients,” Journal of Nuclear Medicine, vol. 44, no. 7, pp. 999–1005, 2003. View at Scopus
24. C. R. Freed, P. E. Greene, R. E. Breeze et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
25. Y. Ma, C. Tang, T. Chaly et al., “Dopamine cell implantation in Parkinson's disease: long-term clinical and ¹⁸F-FDOPA PET outcomes,” Journal of Nuclear Medicine, vol. 51, no. 1, pp. 7–15, 2010. View at Publisher · View at Google Scholar · View at Scopus
26. W. J. Marks Jr., J. L. Ostrem, L. Verhagen et al., “Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial,” The Lancet Neurology, vol. 7, no. 5, pp. 400–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
27. M. Ernst, A. J. Zametkin, J. A. Matochik, D. Pascualvaca, P. H. Jons, and R. M. Cohen, “High midbrain [¹⁸F]DOPA accumulation in children with attention deficit hyperactivity disorder,” American Journal of Psychiatry, vol. 156, no. 8, pp. 1209–1215, 1999. View at Scopus
28. N. H. Patel, N. S. Vyas, B. K. Puri, K. S. Nijran, and A. Al-Nahhas, “Positron emission tomography in schizophrenia: a new perspective,” Journal of Nuclear Medicine, vol. 51, no. 4, pp. 511–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
29. O. D. Howes, A. J. Montgomery, M. C. Asselin et al., “Elevated striatal dopamine function linked to prodromal signs of schizophenia,” Archives of General Psychiatry, vol. 66, no. 1, pp. 13–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
30. J. L. Eberling, W. J. Jagust, C. W. Christine et al., “Results from a phase I safety trial of hAADC gene therapy for Parkinson disease,” Neurology, vol. 70, no. 21, pp. 1980–1983, 2008. View at Publisher · View at Google Scholar · View at Scopus
31. S. I. Muramatsu, K. I. Fujimoto, S. Kato et al., “A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson's disease,” Molecular Therapy, vol. 18, no. 9, pp. 1731–1735, 2010. View at Publisher · View at Google Scholar · View at Scopus
32. J. Shi, L. Y. Zhao, M. L. Copersino et al., “PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users,” European Journal of Pharmacology, vol. 579, no. 1–3, pp. 160–166, 2008. View at Publisher · View at Google Scholar · View at Scopus
33. T. J. Spencer, J. Biederman, B. K. Madras et al., “In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter,” Biological Psychiatry, vol. 57, no. 11, pp. 1293–1300, 2005. View at Publisher · View at Google Scholar · View at Scopus
34. N. Quinn, “A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism,” Neurology, vol. 57, no. 4, pp. 746–747, 2001. View at Scopus
35. S. Asenbaum, W. Pirker, P. Angelberger, G. Bencsits, M. Pruckmayer, and T. Brucke, “[¹²³I] β-CIT and SPECT in essential tremor and Parkinson's disease,” Journal of Neural Transmission, vol. 105, no. 10–12, pp. 1213–1228, 1998. View at Publisher · View at Google Scholar
36. R. T. Malison, S. E. Best, C. H. van Dyck et al., “Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [¹²³I]β-CIT SPECT,” American Journal of Psychiatry, vol. 155, no. 6, pp. 832–834, 1998. View at Scopus
37. L. K. Jacobsen, J. K. Staley, R. T. Malison et al., “Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients,” American Journal of Psychiatry, vol. 157, no. 7, pp. 1134–1140, 2000. View at Publisher · View at Google Scholar · View at Scopus
38. C. H. van Dyck, D. M. Quinlan, L. M. Cretella et al., “Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder,” American Journal of Psychiatry, vol. 159, no. 2, pp. 309–312, 2002. View at Publisher · View at Google Scholar · View at Scopus
39. J. Booij, J. D. Speelman, M. W. I. M. Horstink, and E. C. Wolters, “The clinical benefit of imaging striatal dopamine transporters with [¹²³I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism,” European Journal of Nuclear Medicine, vol. 28, no. 3, pp. 266–272, 2001. View at Publisher · View at Google Scholar · View at Scopus
40. W. Koch, C. Hamann, P. E. Radau, and K. Tatsch, “Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 8, pp. 1265–1273, 2007. View at Publisher · View at Google Scholar · View at Scopus
41. M. Plotkin, H. Amthauer, S. Klaffke et al., “Combined ¹²³I-FP-CIT and ¹²³I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients,” Journal of Neural Transmission, vol. 112, no. 5, pp. 677–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
42. T. S. Benamer, J. Patterson, D. G. Grosset et al., “Accurate differentiation of parkinsonism and essential tremor using visual assessment of [¹²³I]-FP-CIT SPECT imaging: the [¹²³I]-FP-CIT study group,” Movement Disorders, vol. 15, no. 3, pp. 503–510, 2000. View at Publisher · View at Google Scholar · View at Scopus
43. S. Colloby and J. O'Brien, “Functional imaging in Parkinson's disease and dementia with Lewy bodies,” Journal of Geriatric Psychiatry and Neurology, vol. 17, no. 3, pp. 158–163, 2004. View at Publisher · View at Google Scholar · View at Scopus
44. J. T. O'Brien, S. Colloby, J. Fenwick et al., “Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies,” Archives of Neurology, vol. 61, no. 6, pp. 919–925, 2004. View at Publisher · View at Google Scholar · View at Scopus
45. R. Larisch, W. Sitte, C. Antke et al., “Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder,” Nuclear Medicine Communications, vol. 27, no. 3, pp. 267–270, 2006. View at Publisher · View at Google Scholar · View at Scopus
46. S. Hesse, O. Ballaschke, H. Barthel, and O. Sabri, “Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder,” Psychiatry Research, vol. 171, no. 2, pp. 120–128, 2009. View at Publisher · View at Google Scholar · View at Scopus
47. J. S. H. Vles, F. J. M. Feron, J. G. M. Hendriksen, J. Jolles, M. J. P. G. van Kroonenburgh, and W. E. J. Weber, “Methylphenidate down-regulates the dopamine receptor and transporter system in children with Attention Deficit Hyperkinetic Disorder (ADHD),” Neuropediatrics, vol. 34, no. 2, pp. 77–80, 2003. View at Publisher · View at Google Scholar · View at Scopus
48. J. J. Mateos, F. Lomeña, E. Parellada et al., “Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait,” Psychopharmacology, vol. 191, no. 3, pp. 805–811, 2007. View at Publisher · View at Google Scholar · View at Scopus
49. W. S. Huang, S. Z. Lin, J. C. Lin, S. P. Wey, G. Ting, and R. S. Liu, “Evaluation of early-stage Parkinson's disease with ${}^{99m}\text{Tc}$-TRODAT-1 imaging,” Journal of Nuclear Medicine, vol. 42, no. 9, pp. 1303–1308, 2001. View at Scopus
50. Y. H. Weng, T. C. Yen, M. C. Chen et al., “Sensitivity and specificity of ${}^{99m}\text{Tc}$-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 393–401, 2004. View at Scopus
51. C. M. Chen, C. H. Lin, H. F. Juan et al., “ATP13A2 variability in Taiwanese Parkinson's disease,” American Journal of Medical Genetics B, vol. 156, no. 6, pp. 720–729, 2011. View at Publisher · View at Google Scholar
52. C. S. Lu, Y. H. Weng, M. C. Chen et al., “${}^{99m}\text{Tc}$-TRODAT-1 imaging of multiple system atrophy,” Journal of Nuclear Medicine, vol. 45, no. 1, pp. 49–55, 2004. View at Scopus
53. K. Y. Tzen, C. S. Lu, T. C. Yen, S. P. Wey, and G. Ting, “Differential diagnosis of Parkinson's disease and vascular parkinsonism by ${}^{99m}\text{Tc}$-TRODAT-1,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 408–413, 2001. View at Scopus
54. C. C. Huang, T. C. Yen, Y. H. Weng, and C. S. Lu, “Normal dopamine transporter binding in dopa responsive dystonia,” Journal of Neurology, vol. 249, no. 8, pp. 1016–1020, 2002. View at Publisher · View at Google Scholar · View at Scopus
55. W. Y. Lin, K. J. Lin, Y. H. Weng et al., “Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy,” Nuclear Medicine Communications, vol. 31, no. 11, pp. 974–980, 2010. View at Publisher · View at Google Scholar · View at Scopus
56. Y. H. Weng, Y. H. W. Chou, W. S. Wu et al., “PINK1 mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies,” Journal of Neurology, vol. 254, no. 10, pp. 1347–1355, 2007. View at Publisher · View at Google Scholar · View at Scopus
57. T. C. Yen, K. Y. Tzen, M. C. Chen et al., “Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers,” Journal of Nuclear Medicine, vol. 43, no. 2, pp. 153–159, 2002. View at Scopus
58. P. Crits-Christoph, A. Newberg, N. Wintering et al., “Dopamine transporter levels in cocaine dependent subjects.,” Drug and Alcohol Dependence, vol. 98, no. 1-2, pp. 70–76, 2008. View at Scopus
59. T. L. Yeh, K. C. Chen, S. H. Lin, et al., “Availability of dopamine and serotonin transporters in opioid-dependent users—a two-isotope SPECT study,” Psychopharmacology, vol. 220, no. 1, pp. 55–64, 2012. View at Publisher · View at Google Scholar
60. Y. K. Yang, W. J. Yao, T. L. Yeh et al., “Decreased dopamine transporter availability in male smokers—a dual isotope SPECT study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 1, pp. 274–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
61. A. Newberg, C. Lerman, N. Wintering, K. Ploessl, and P. D. Mozley, “Dopamine transporter binding in smokers and nonsmokers,” Clinical Nuclear Medicine, vol. 32, no. 6, pp. 452–455, 2007. View at Publisher · View at Google Scholar · View at Scopus
62. K. H. Krause, S. H. Dresel, J. Krause, C. la Fougere, and M. Ackenheil, “The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder,” Neuroscience and Biobehavioral Reviews, vol. 27, no. 7, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
63. J. Krause, “SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder,” Expert Review of Neurotherapeutics, vol. 8, no. 4, pp. 611–625, 2008. View at Publisher · View at Google Scholar · View at Scopus
64. S. Dresel, J. Krause, K. H. Krause et al., “Attention deficit hyperactivity disorder: binding of [${}^{99m}\text{Tc}$]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment,” European Journal of Nuclear Medicine, vol. 27, no. 10, pp. 1518–1524, 2000. View at Publisher · View at Google Scholar · View at Scopus
65. K. H. Krause, S. H. Dresel, J. Krause, H. F. Kung, and K. Tatsch, “Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography,” Neuroscience Letters, vol. 285, no. 2, pp. 107–110, 2000. View at Publisher · View at Google Scholar · View at Scopus
66. J. Krause, C. la Fougere, K. H. Krause, M. Ackenheil, and S. H. Dresel, “Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD,” European Archives of Psychiatry and Clinical Neuroscience, vol. 255, no. 6, pp. 428–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
67. C. La Fougère, J. Krause, K. H. Krause et al., “Value of ${}^{99m}\text{Tc}$-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder,” Nuclear Medicine Communications, vol. 27, no. 9, pp. 733–737, 2006. View at Publisher · View at Google Scholar
68. K. H. Krause, S. H. Dresel, J. Krause, H. F. Kung, K. Tatsch, and M. Ackenheil, “Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder,” International Journal of Neuropsychopharmacology, vol. 5, no. 2, pp. 111–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
69. D. D. Dougherty, A. A. Bonab, T. J. Spencer, S. L. Rauch, B. K. Madras, and A. J. Fischman, “Dopamine transporter density in patients with attention deficit hyperactivity disorder,” The Lancet, vol. 354, no. 9196, pp. 2132–2133, 1999. View at Scopus
70. K. A. Cheon, Y. H. Ryu, Y. K. Kim, K. Namkoong, C. H. Kim, and J. D. Lee, “Dopamine transporter density in the basal ganglia assessed with [¹²³I]IPT SPET in children with attention deficit hyperactivity disorder,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 2, pp. 306–311, 2003. View at Scopus
71. A. Abi-Dargham, O. Mawlawi, I. Lombardo et al., “Prefrontal dopamine D1 receptors and working memory in schizophrenia,” Journal of Neuroscience, vol. 22, no. 9, pp. 3708–3719, 2002. View at Scopus
72. Y. Okubo, T. Suhara, K. Suzuki et al., “Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET,” Nature, vol. 385, no. 6617, pp. 634–635, 1997. View at Publisher · View at Google Scholar · View at Scopus
73. P. Karlsson, L. Farde, C. Halldin, and G. Sedvall, “PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia,” American Journal of Psychiatry, vol. 159, no. 5, pp. 761–767, 2002. View at Publisher · View at Google Scholar · View at Scopus
74. N. D. Volkow, J. S. Fowler, and G. J. Wang, “The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies,” Neuropharmacology, vol. 47, supplement 1, pp. S3–S13, 2004. View at Publisher · View at Google Scholar · View at Scopus
75. N. D. Volkow, J. S. Fowler, G. J. Wang, J. M. Swanson, and F. Telang, “Dopamine in drug abuse and addiction: results of imaging studies and treatment implications,” Archives of Neurology, vol. 64, no. 11, pp. 1575–1579, 2007. View at Publisher · View at Google Scholar · View at Scopus
76. N. D. Volkow, J. S. Fowler, G. J. Wang, and J. M. Swanson, “Dopamine in drug abuse and addiction: results from imaging studies and treatment implications,” Molecular Psychiatry, vol. 9, no. 6, pp. 557–569, 2004. View at Publisher · View at Google Scholar · View at Scopus
77. N. D. Volkow, J. S. Fowler, G. J. Wang, R. Baler, and F. Telang, “Imaging dopamine's role in drug abuse and addiction,” Neuropharmacology, vol. 56, supplement 1, pp. S3–S8, 2009. View at Publisher · View at Google Scholar · View at Scopus
78. N. D. Volkow, G. J. Wang, J. S. Fowler et al., “Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D₂ receptors,” Journal of Pharmacology and Experimental Therapeutics, vol. 291, no. 1, pp. 409–415, 1999. View at Scopus
79. N. D. Volkow, G. J. Wang, J. S. Fowler et al., “Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D₂ receptor levels,” American Journal of Psychiatry, vol. 156, no. 9, pp. 1440–1443, 1999. View at Scopus
80. N. D. Volkow, G. J. Wang, M. W. Fischman et al., “Relationship between subjective effects of cocaine and dopamine transporter occupancy,” Nature, vol. 386, no. 6627, pp. 827–830, 1997. View at Scopus
81. N. D. Volkow, J. S. Fowler, G. J. Wang et al., “Decreased dopamine D₂ receptor availability is associated with reduced frontal metabolism in cocaine abusers,” Synapse, vol. 14, no. 2, pp. 169–177, 1993. View at Publisher · View at Google Scholar · View at Scopus
82. N. D. Volkow, L. Chang, G. J. Wang et al., “Low level of brain dopamine D₂ receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex,” American Journal of Psychiatry, vol. 158, no. 12, pp. 2015–2021, 2001. View at Publisher · View at Google Scholar · View at Scopus
83. G. J. Wang, N. D. Volkow, J. S. Fowler et al., “Dopamine D₂ receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal,” Neuropsychopharmacology, vol. 16, no. 2, pp. 174–182, 1997. View at Publisher · View at Google Scholar · View at Scopus
84. N. D. Volkow, G. J. Wang, J. S. Fowler et al., “Decreases in dopamine receptors but not in dopamine transporters in alcoholics,” Alcoholism: Clinical and Experimental Research, vol. 20, no. 9, pp. 1594–1598, 1996. View at Scopus
85. N. D. Volkow, G. Wang, J. S. Fowler et al., “Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain,” The Journal of Neuroscience, vol. 21, no. 2, Article ID RC121, 2001. View at Scopus
86. N. D. Volkow, G. J. Wang, J. S. Fowler et al., “Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications,” Synapse, vol. 43, no. 3, pp. 181–187, 2002. View at Publisher · View at Google Scholar · View at Scopus
87. L. Farde, S. Pauli, H. Hall et al., “Stereoselective binding of 11C-raclopride in living human brain—a search for extrastriatal central D-2 dopamine receptors by PET,” Psychopharmacology, vol. 94, no. 4, pp. 471–478, 1988. View at Scopus
88. M. Nord and L. Farde, “Antipsychotic occupancy of dopamine receptors in schizophrenia,” CNS Neuroscience and Therapeutics, vol. 17, no. 2, pp. 97–103, 2011. View at Publisher · View at Google Scholar
89. S. Kasper, J. Tauscher, B. Küfferle, C. Barnas, L. Pezawas, and S. Quiner, “Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implicationsfor pharmacotherapy in schizophrenia,” European Archives of Psychiatry and Clinical Neuroscience, vol. 249, supplement 4, pp. S83–S89, 1999.
90. A. Abi-Dargham, J. Rodenhiser, D. Printz et al., “Increased baseline occupancy of D₂ receptors by dopamine in schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 14, pp. 8104–8109, 2000. View at Publisher · View at Google Scholar · View at Scopus
91. J. Tauscher, B. Küfferle, S. Asenbaum, S. Tauscher-Wisniewski, and S. Kasper, “Striatal dopamine-2 receptor occupancy as measured with [¹²³I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol,” Psychopharmacology, vol. 162, no. 1, pp. 42–49, 2002. View at Publisher · View at Google Scholar · View at Scopus
92. S. Kasper, J. Tauscher, E. Küfferle, B. Hesselmann, C. Barnas, and T. Brücke, “IBZM-SPECT imaging of dopamine D₂ receptors with typical and atypical antipsychotics,” European Psychiatry, vol. 13, supplement 1, pp. S9–S14, 1998. View at Scopus
93. N. Okamura, V. L. Villemagne, J. Drago et al., “In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with ¹⁸F-AV-133,” Journal of Nuclear Medicine, vol. 51, no. 2, pp. 223–228, 2010. View at Publisher · View at Google Scholar · View at Scopus
94. V. L. Villemagne, N. Okamura, S. Pejoska et al., “In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease,” Archives of Neurology, vol. 68, no. 7, pp. 905–912, 2011. View at Publisher · View at Google Scholar
95. H. F. Kung, Y. Z. Guo, J. Billings et al., “Preparation and biodistribution of [¹²⁵I]IBZM: a potential CNS D-2 dopamine receptor imaging agent,” International Journal of Radiation Applications and Instrumentation B, vol. 15, no. 2, pp. 195–201, 1988. View at Scopus
96. H. F. Kung, S. Pan, M. P. Kung et al., “In vitro and in vivo evaluation of [¹²³I]IBZM: a potential CNS D-2 dopamine receptor imaging agent,” Journal of Nuclear Medicine, vol. 30, no. 1, pp. 88–92, 1989. View at Scopus
97. L. H. Pinborg, C. Videbaek, M. Ziebell et al., “[¹²³I]epidepride binding to cerebellar dopamine D₂/D₃ receptors is displaceable: implications for the use of cerebellum as a reference region,” Neuroimage, vol. 34, no. 4, pp. 1450–1453, 2007. View at Publisher · View at Google Scholar · View at Scopus
98. N. I. Bohnen and K. A. Frey, “Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders,” Molecular Imaging and Biology, vol. 9, no. 4, pp. 243–257, 2007. View at Publisher · View at Google Scholar · View at Scopus
99. W. Lu and M. E. Wolf, “Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration,” Molecular Brain Research, vol. 49, no. 1-2, pp. 137–148, 1997. View at Publisher · View at Google Scholar · View at Scopus
100. K. J. Lin, Y. H. Weng, S. P. Wey et al., “Whole-body biodistribution and radiation dosimetry of ¹⁸F-FP-(+) -DTBZ (¹⁸F-AV-133): a novel vesicular monoamine transporter 2 imaging agent,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1480–1485, 2010. View at Publisher · View at Google Scholar · View at Scopus
101. D. J. Gelb, E. Oliver, and S. Gilman, “Diagnostic criteria for Parkinson disease,” Archives of Neurology, vol. 56, no. 1, pp. 33–39, 1999. View at Publisher · View at Google Scholar · View at Scopus
102. E. Tolosa, G. Wenning, and W. Poewe, “The diagnosis of Parkinson's disease,” The Lancet Neurology, vol. 5, no. 1, pp. 75–86, 2006. View at Publisher · View at Google Scholar · View at Scopus
103. R. Pahwa and K. E. Lyons, “Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines,” The American Journal of Managed Care, vol. 16, supplement 4, pp. S94–99, 2010. View at Scopus
104. A. J. Hughes, S. E. Daniel, S. Blankson, and A. J. Lees, “A clinicopathologic study of 100 cases of Parkinson's disease,” Archives of Neurology, vol. 50, no. 2, pp. 140–148, 1993. View at Scopus
105. A. H. Rajput, B. Rozdilsky, and A. Rajput, “Accuracy of clinical diagnosis in Parkinsonism—a prospective study,” Canadian Journal of Neurological Sciences, vol. 18, no. 3, pp. 275–278, 1991. View at Scopus
106. A. Antonini, “Imaging for early differential diagnosis of parkinsonism,” The Lancet Neurology, vol. 9, no. 2, pp. 130–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
107. A. C. Felicio, M. C. Shih, C. Godeiro-Junior, L. A. F. Andrade, R. A. Bressan, and H. B. Ferraz, “Molecular imaging studies in Parkinson disease reducing diagnostic uncertainty,” Neurologist, vol. 15, no. 1, pp. 6–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
108. A. M. M. Vlaar, T. de Nijs, A. G. H. Kessels et al., “Diagnostic value of ¹²³I-ioflupane and ¹²³I- iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes,” European Neurology, vol. 59, no. 5, pp. 258–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
109. B. Thanvi, N. Lo, and T. Robinson, “Vascular parkinsonism—an important cause of parkinsonism in older people,” Age and Ageing, vol. 34, no. 2, pp. 114–119, 2005. View at Publisher · View at Google Scholar · View at Scopus
110. A. L. Berry and T. Foltynie, “Gene therapy: a viable therapeutic strategy for Parkinson's disease?” Journal of Neurology, vol. 258, no. 2, pp. 179–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
111. L. Leriche, T. Björklund, N. Breysse et al., “Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy,” Journal of Neuroscience, vol. 29, no. 5, pp. 1544–1553, 2009. View at Publisher · View at Google Scholar · View at Scopus
112. M. G. Kaplitt, A. Feigin, C. Tang et al., “Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial,” The Lancet, vol. 369, no. 9579, pp. 2097–2105, 2007. View at Publisher · View at Google Scholar · View at Scopus
113. N. D. Volkow, G. J. Wang, J. S. Fowler et al., “Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects,” Nature, vol. 386, no. 6627, pp. 830–833, 1997. View at Scopus
114. N. D. Volkow, Y. S. Ding, J. S. Fowler et al., “Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain,” Archives of General Psychiatry, vol. 52, no. 6, pp. 456–463, 1995. View at Scopus
115. M. V. Solanto, “Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration,” Behavioural Brain Research, vol. 94, no. 1, pp. 127–152, 1998. View at Publisher · View at Google Scholar · View at Scopus
116. A. Abi-Dargham, “Do we still believe in the dopamine hypothesis? New data bring new evidence,” International Journal of Neuropsychopharmacology, vol. 7, supplement 1, pp. S1–S5, 2004. View at Scopus
117. O. Langer and C. Halldin, “PET and SPET tracers for mapping the cardiac nervous system,” European Journal of Nuclear Medicine, vol. 29, no. 3, pp. 416–434, 2002. View at Publisher · View at Google Scholar · View at Scopus
118. A. Takano, “The application of PET technique for the development and evaluation of novel antipsychotics,” Current Pharmaceutical Design, vol. 16, no. 3, pp. 371–377, 2010. View at Publisher · View at Google Scholar · View at Scopus
119. C. Hiemke, “Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?” European Archives of Psychiatry and Clinical Neuroscience, vol. 258, supplement 1, pp. S21–S27, 2008. View at Publisher · View at Google Scholar · View at Scopus
120. S. Kapur, R. Zipursky, C. Jones, G. Remington, and S. Houle, “Relationship between dopamine D₂ occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia,” American Journal of Psychiatry, vol. 157, no. 4, pp. 514–520, 2000. View at Publisher · View at Google Scholar · View at Scopus